SCHEMBL2968098

SCHEMBL2968098

CCCCc1ccc2c(Nc3cc(C)ccc3Sc3ccc(NC(C)=O)cc3)ccnc2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SREBF2 Q12772 1/20 0.39
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
PKM P14618 1/20 0.38
HPGD P15428 1/20 0.38
KDM4E B2RXH2 3/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
TP53 P04637 2/20 0.36
LMNA P02545 1/20 0.36
ALDH1A1 P00352 4/20 0.36
MAPT P10636 3/20 0.36
JAK2 O60674 1/20 0.36
NPC1 O15118 1/20 0.35
MAPK1 P28482 1/20 0.35
BLM P54132 3/20 0.35
POLB P06746 1/20 0.35
NR1I2 O75469 1/20 0.35
AHR P35869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2961153 0.95 SREBF2 (0.44) SREBF2AURKAAURKBSMN1; SMN2PKM
SCHEMBL2018147 0.92 AURKA (0.39) SREBF2AURKAAURKBSMN1; SMN2PKM
SCHEMBL2961423 0.92 AURKA (0.40) SREBF2AURKAAURKBSMN1; SMN2PKM
SCHEMBL2971544 0.89 AURKA (0.38) SREBF2AURKAAURKBSMN1; SMN2PKM
SCHEMBL2970848 0.88 AURKA (0.37) SREBF2AURKAAURKBSMN1; SMN2PKM
SCHEMBL27733758 0.88 AURKA (0.36) SREBF2AURKAAURKBSMN1; SMN2PKM
SCHEMBL2023477 0.87 AURKA (0.41) AURKAAURKBSMN1; SMN2PKMHPGD
SCHEMBL2965361 0.86 SREBF2 (0.44) SREBF2AURKAAURKBSMN1; SMN2KDM4E
SCHEMBL2016780 0.86 AURKA (0.40) AURKAAURKBSMN1; SMN2PKMHPGD
SCHEMBL2955721 0.85 KDR (0.39) SREBF2AURKAAURKBSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 SREBF2 876/4885AURKA 2172/4885AURKB 2041/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 SREBF2 876/4885AURKA 2172/4885AURKB 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.